Abstract The GABA A receptor is implicated in the pathophysiology of schizophrenia and regulated by PKA signalling. Current antipsychotics bind with D 2 -like receptors, but not the GABA A receptor. The cAMP-responsive element-binding protein 1 (CREB1) is also associated with PKA signalling and may be related to the positive symptoms of schizophrenia. This study investigated the effects of antipsychotics in modulating D 2 -mediated PKA signalling and its downstream GABA A receptors and CREB1. Rats were treated orally with aripiprazole (0.75 mg/kg, ter in die (t.i.d.)), bifeprunox (0.8 mg/kg, t.i.d.), haloperidol (0.1 mg/kg, t.i.d.) or vehicle for 1 week. The levels of PKA-Cα and p-PKA in the prefrontal cortex (PFC), nucleus accumbens (NAc) and caudate putamen (CPu) were detected by Western blots. The mRNA levels of Gabrb1, Gabrb2, Gabrb3 and Creb1, and their protein expression were measured by qRT-PCR and Western blots, respectively. Aripiprazole elevated the levels of p-PKA and the ratio of p-PKA/PKA in the NAc, but not the PFC and CPu. Correlated with this elevated PKA signalling, aripiprazole elevated the mRNA and protein expression of the GABA A (β-1) receptor and CREB1 in the NAc. While haloperidol elevated the levels of p-PKA and the ratio of p-PKA/ PKA in both NAc and CPu, it only tended to increase the expression of the GABA A (β-1) receptor and CREB1 in the NAc, but not the CPu. Bifeprunox had no effects on PKA signalling in these brain regions. These results suggest that aripiprazole has selective effects on upregulating the GABA A (β-1) receptor and CREB1 in the NAc, probably via activating PKA signalling.
Introduction
Gamma-aminobutyric acid (GABA) is one of the major inhibitory neurotransmitters and has been reported to be involved in the pathophysiology of schizophrenia (see review Benes 2015) . The GABA receptor family consists of three classes of receptors-GABA A , GABA B and GABA C ; the GABA A receptor is widely distributed in the brain (Hendry et al. 1989) . Previous studies reported abnormal GABA A receptor density in various brain regions of schizophrenia subjects, including the prefrontal cortex (PFC) (Dean et al. 1999; Ishikawa et al. 2004) , cingulate cortex (Benes et al. 1992) , superior temporal gyrus (Deng and Huang 2006) and hippocampus (Benes et al. 1997) . Antipsychotic drug administration also affects GABA A receptors. For example, a 6-month treatment with haloperidol increased the density of GABA A receptor binding of [ 3 H]-muscimol in the caudate putamen (CPu), the core of the nucleus accumbens (NAc), while reducing it in the parietal and temporal cortex; both haloperidol and clozapine increased the bindings of GABA A receptors in the anterior cingulate and infralimbic cortex, respectively (Zink et al. 2004) . Skilbeck et al. (2007) reported that the total population of GABA A receptors was increased by 1-week treatment with haloperidol and olanzapine; however, antipsychotic effects diminished in the longer treatment groups. Additionally, McLeod et al. (2008) found that administration with haloperidol decreased the GABA A binding site in the thalamus but increased binding sites in the hypothalamus. It is worth noting that none of the antipsychotics directly binds with GABA A receptors, which raises a critical question: which pathway(s) do antipsychotics act on to affect the GABA A receptors?
All current antipsychotics act on D 2 -like receptors (including D 2 , D 3 and D 4 ) to achieve their therapeutic effects. Typical antipsychotic drugs (e.g. haloperidol) can potently block D 2 -like receptors, being effective in alleviating the positive symptoms of schizophrenia (such as delusions, hallucination, disordered speech, behaviours, etc.), but inducing severe extrapyramidal side effects (EPS; such as acute dyskinesias and dystonic reactions, tardive dyskinesia, Parkinsonism, etc.) (Kapur and Mamo 2003) . Furthermore, although binding to multiple receptors (including serotonin 5-HT 2A , 5-HT 2C , muscarinic receptors), the majority of the atypical antipsychotics (e.g. clozapine, olanzapine and risperidone) also antagonise D 2 Rs (Kapur and Mamo 2003) . In recent years, partial agonists for D 2 -like receptors were the focus of the new drug development. Aripiprazole is a successful D 2 partial agonist that possesses therapeutic effects in schizophrenia, with much lower EPS side effects (Mailman and Murthy 2010) . However, to date, all other partial agonists, except aripiprazole, failed to achieve meaningful clinical efficacy for schizophrenia or were discontinued due to tolerability and/or safety issues (Benkert et al. 1995; Lahti et al. 1998) . Recently, bifeprunox, a potent partial agonist for the dopamine D 2 receptor, exhibited therapeutic effects in clinical trials (Casey et al. 2008 ) but was still disapproved and cancelled due to severe side effects (e.g. nausea) and unstable long-term therapeutic effects (Casey et al. 2008; Lundbeck 2009 ). Therefore, it is necessary to investigate the pharmacological mechanism of aripiprazole by comparing it with other D 2 partial agonists (e.g. bifeprunox).
The G protein-dependent cAMP-PKA pathway is a major downstream signalling pathway of D 2 -like receptors, in which activation of D 2 -like receptors inhibits the activity of adenylate cyclase and synthesis of cAMP via the G i protein, followed by the inhibition of PKA signalling (Beebe 1994) . A postmortem study found reduced PKA regulatory subunits in schizophrenia patients (Tardito et al. 2000) , indicating that PKA signalling may be related to the pathophysiology of schizophrenia. In vivo studies have suggested that PKA signalling may be involved in the clinical effects of antipsychotics. For example, acute haloperidol and olanzapine treatment can increase the expression of PKA catalytic subunits in the CPu in rats (Turalba et al. 2004) ; another study indicated that haloperidol facilitated this signalling (Kaneko et al. 1992) ; furthermore, the activity of the cAMP-PKA pathway and expression of PKA regulatory subunits in the striatum were elevated after 3-week treatment with haloperidol, whereas clozapine displayed opposite effects in various brain areas (Dwivedi et al. 2002) .
PKA kinase regulates several downstream substrates that are involved in the pathophysiology of schizophrenia. The GABA A receptor can be regulated by D 2 -like receptormediated PKA signalling (Connelly et al. 2013 ). In addition, cAMP-responsive element-binding protein (CREB) is another PKA downstream substrate (Shaywitz and Greenberg 1999) . Novel variants in the CREB gene have been identified in schizophrenic patients who have experienced the positive symptoms of schizophrenia (Kawanishi et al. 1999) . Previous studies revealed that haloperidol increased phosphorylation levels of CREB in both in vivo and in vitro studies (Konradi and Heckers 1995; Pozzi et al. 2003; Yang et al. 2004) . Both amisulpride and clozapine can also induce the phosphorylation of CREB in vitro (Jeon et al. 2015; Park et al. 2011) . Therefore, we proposed that antipsychotic drugs may modulate GABA A receptors and CREB1 activity through the PKA signalling pathway. The present study investigated the effects of antipsychotics on the PKA downstream GABA A receptors and CREB1.
Methods

Animals and Drug Administration
Male Sprague-Dawley rats (aged 8 weeks) were obtained from the Animal Resource Centre (Perth, Australia). After arrival, all rats were housed in individual cages under environmentally controlled conditions (temperature 22°C, light cycle from 07:00 AM to 07:00 PM), with ad libitum access to water and standard laboratory chow diet. All experimental procedures were approved by the Animal Ethics Committee (application no. AE11/02), University of Wollongong, and complied with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes (2004) . All animals were euthanised using carbon dioxide. All efforts were made to minimise animal distress and prevent suffering.
Before the drug administration commenced, the rats were fed with cookie dough (containing sucrose 30.9 %, cornstarch 30.9 %, casein 15.5 %, minerals 8.4 %, fibre 6.4 %, gelatine 6.3 % and vitamins 1.6 %) without drugs for 1 week to train them to self-administrate the drug. Then, rats were randomly assigned into one of the following drug groups (n = 6/group) and orally treated with cookie dough mixed with the drug powder: aripiprazole (0.75 mg/kg, ter in die (t.i.d.); Otsuka, Japan), bifeprunox (0.8 mg/kg, t.i.d.; Otava, Ukraine), haloperidol (0.1 mg/kg, t.i.d.; Sigma, Australia) or vehicle for 1 week. Water was added to achieve a dry-dough consistency immediately prior to administration. Rats were offered cookies with drugs by a metal spoon three times a day (at 06:00 AM, 02:00 PM and 10:00 PM) and observed to ensure complete consumption of each pellet. These dosages were equivalent to the recommended dosage in the clinic, and they were translated based on body surface area according to the FDA guidelines for clinical trials (FDA 2005; Reagan-Shaw et al. 2008 ). This drug administration method has been well established in our laboratory (De Santis et al. 2014; Deng et al. 2015) . A 0.75 mg/kg aripiprazole dosage in rats is equivalent to ∼7.5 mg in humans (60 kg body weight), while 0.8 mg/kg bifeprunox and 0.1 mg/kg haloperidol is equivalent to ∼8 and ∼1 mg, respectively, all of which are within the used/recommended clinical dosages (Casey et al. 2008; Emsley 2009; Mace and Taylor 2009) . It was reported that aripiprazole and bifeprunox, at these dosages, had over 90 % D 2 receptor occupancy in rat brains (Wadenberg 2007) , while haloperidol reached approximately 70 % D 2 R occupancy Naiker et al. 2006; Natesan et al. 2006) . Furthermore, the dosages used in this study have been shown to be physiologically and behaviourally effective in rodents (Assie et al. 2006; De Santis et al. 2014; Han et al. 2009; Kesby et al. 2006; Wadenberg 2007) , whilst not causing EPS side effects (Natesan et al. 2006; Wadenberg 2007) . After 1-week administration, all rats were sacrificed between 10:00 AM and 12:00 PM to minimise possible circadianinduced variation of protein expression. Brains were immediately removed, frozen in liquid nitrogen and stored at −80°C until required.
Microdissection
Following a standard procedure used in our lab, discrete brain regions were collected using brain microdissection puncture, which has been performed successfully . Based on the brain atlas (Paxinos and Watson 2005) , three sections through the forebrain (bregma 3.30 to 4.20 mm) were dissected for the PFC; three sections through the striatum (bregma 1.00 to 2.20 mm) were dissected for the NAc and CPu, respectively. The three brain regions were chosen because they are key brain areas involved in the effects of antipsychotics. Tissue obtained was stored at −80°C until use.
Western Blots
The Western blots procedures were described previously Pan et al. 2015) . Tissue was homogenised with NP-40 cell lysis buffer (Invitrogen, Camarillo, CA, USA) mixed with Protease Inhibitor Cocktail (Sigma-Aldrich, St Louis, MO, USA), β-glycerophosphate (Invitrogen) and phenylmethylsulfonylfluoride (Sigma-Aldrich). The homogenised samples were centrifuged, and the supernatants were collected. Protein concentrations of the supernatants were determined spectrophotometrically using the DC Protein Assay (Bio-Rad, #500-0111). Samples containing 10 μg of protein were resolved by 10 % SDS-PAGE gels, and then transferred electrophoretically to a polyvinylidene difluoride membrane using Bio-Rad Midi Format 1-D Electrophoresis Systems. The membranes were blocked by 5 % skim milk and incubated in primary antibodies. Amersham Hyperfilm ECL (GE Healthcare, #28-9068-36) was used to visualise the immunoreactive bands. The immunoreactive signals were quantified using Bio-Rad Quantity One software. The data were normalised to the corresponding actin levels. Experiments of Western blots were performed in duplicate to ensure consistency.
Two catalytic (Cα and Cβ) isoform of PKA subunits have been previously identified (Cadd and McKnight 1989) . PKA-Cα expression was measured due to its highest expression in brain tissues (Soberg et al. 2013; Uhler et al. 1986 ). Therefore, two antibodies for PKA subunits were chosen in the present study: anti-PKA-Cα (1:1000; Santa Cruz, #SC-903) and anti-phosphor-PKA-C (Thr197) (1:1000; Cell Signalling, #5661). Subunits of GABA A receptors and CREB1 were examined using anti-GABA A β-1 (1:1000; Abcam, #ab154822), anti-GABA A β-2 (1:1000; Abcam, #ab156000), anti-GABA A β-3 (1:1000; Abcam, #ab98968) and anti-CREB1 (1:1000; Abcam, #ab32515). Mouse anti-actin primary polyclonal antibody (1:10,000; Millipore, #MAB1501) were used to determine the actin levels. The secondary antibodies used in this study were HRP-linked anti-rabbit IgG antibody (1:3000; Cell Signalling, #7074) and HRP-linked anti-mouse IgG antibody (1:3000; Cell Signalling, #7076).
RNA Isolation and Related Quantitative Real-Time PCR
Quantitative real-time polymerase chain reaction (qRT-PCR) was employed to measure the mRNA expression levels of Gabrb1, Gabrb2, Gabrb3 and Creb1 in the brain regions where the PKA signalling was significantly affected by antipsychotic drug administration. The qRT-PCR procedures were described previously (Liu et al. 2015) . Briefly, PureLink® RNA Mini Kit (Invitrogen Life Technologies, Carlsbad, CA, USA) was used to extract RNA. First-strand cDNA was synthesised from RNA with Superscript® VILO™ cDNA Synthesis Kit (Life Technologies, NSW, Australia) by incubation at 42°C for 60 min. Then, each sample cDNA was performed qRT-PCR in duplicate using TaqMan® Gene Expression Assays (Applied Biosystems, Foster City, USA) on LightCycler® 480 (Roche, Penzberg, Germany). The assay (Life Technologies, NSW, Australia) identifications of the target genes were Gabrb1 (Rn00564146_m1), Gabrb2 (Rn00564149_m1), Gabrb3 (Rn00567029_m1) and Creb1 (Rn00578828_g1). All gene expression levels were normalised relative to two endogenous control genes glyceraldehyde-3-phosphatedehydrogenase (GAPDH) (Rn01775763_g1) and β-actin (Rn00667869_m1). The 2-ΔΔCT method was used to calculate the results.
Statistics
All data were analysed using the SPSS Statistics v22.0 programme. The data of both Western blots and qRT-PCR experiments were normalised by taking the average value of the control group as 100 % and expressed as mean ± SEM. The individual control value was also normalised to the average of overall control experiments for statistical analysis. The phosphorylated protein p-PKA was normalised by the levels of total PKA-Cα. Normality test was performed to test data distribution. One-way analysis of variance (ANOVA) was performed if the data was normally distributed, followed by post hoc Dunnett t test to compare the control and each drug treatment group. Pearson's correlation test was used to analyse the relationships among the measurements. Statistical significance was accepted when p < 0.05.
Results
Antipsychotic Drug Effects on PKA Signalling PFC The expression of PKA-Cα subunits in the PFC was significantly affected by 1-week drug administration (F 3, 20 = 3.723, p < 0.05). In comparison with the control group, administration with aripiprazole induced a significant elevation in the protein levels of PKA-Cα (123.6 ± 3.7 %, p < 0.05) (Fig. 1a, d ). However, no drug significantly affected the levels of p-PKA and the ratio of p-PKA/PKA (Fig. 1a) .
NAc It was shown that antipsychotic drug administration had a significant effect on the levels of p-PKA (F 3, 20 = 13.123, p < 0.01) and the ratio of p-PKA/PKA (F 3, 20 = 3.216, p < 0.05) in the NAc. It was further revealed that administration with both aripiprazole and haloperidol was able to significantly elevate the levels of p-PKA (aripiprazole 134.3 ± 7.0 %, p < 0.01; haloperidol 140.6 ± 6.0 %, p < 0.01) in the NAc (Fig. 1b, d ). The ratio of p-PKA/PKA was also significantly increased by administration with aripiprazole (118.0 ± 7.5 %, p < 0.05) and haloperidol (118.6 ± 3.8 %, p < 0.05) (Fig. 1b) .
CPu In the CPu, drug administration significantly altered the protein levels of PKA-Cα (F 3, 20 = 24.183, p < 0.01) and p-PKA (F 3, 20 = 16.281, p < 0.01) and the ratio of p-PKA/PKA (F 3, 20 = 20.043, p < 0.01). Post hoc tests showed all three chemicals were able to significantly elevate the expression of PKA-Cα in the CPu (aripiprazole 159.3 ± 3.5 %, p < 0.01; bifeprunox 126.7 ± 7.1 %, p < 0.01; haloperidol 125.0 ± 5.4 %, p < 0.01). However, only haloperidol significantly elevated the levels of p-PKA (+88.1 %, p < 0.01) (Fig. 1c, d ). The ratio of p-PKA/PKA was significantly reduced by aripiprazole administration (61.0 ± 1.6 %, p < 0.01), but increased by haloperidol administration (148.5 ± 12.4 %, p < 0.01) (Fig. 1c) .
Antipsychotic Drug Effects on mRNA and Protein Expression of GABA A Subunits and CREB1
Since significant antipsychotic drug effects on the activation of PKA signalling were observed in the NAc and CPu, GABA A receptors and CREB1 were examined in these two brain regions. The results showed that the mRNA expression levels of Gabrb1 (F 3, 20 = 7.898, p < 0.01) were significantly altered by antipsychotic drug administration in the NAc. Furthermore, both aripiprazole and haloperidol administration upregulated the mRNA levels of Gabrb1 (aripiprazole 125.7 ± 4.7 %, p < 0.05; haloperidol 135.2 ± 4.2 %, p < 0.01), whereas the mRNA levels of Gabrb2 and Gabrb3 were not significantly altered by any drug administration (all p > 0.05) (Fig. 2a) . In Western blots, it was revealed that drug administration significantly changed the levels of GABA A β-1 (F 3, 20 = 7.627, p < 0.01) in the NAc. Post hoc tests demonstrated that administration with aripiprazole was able to elevate significantly the levels of GABA A β-1 (164.3 ± 13.1 %, p < 0.01) (Fig. 3a, c) in the NAc; in addition, haloperidol showed trends to increase the expression of GABA A β-1 (126.1 ± 7.3 %, p < 0.1) in the NAc. It is worth noting that the protein levels of GABA A β-1 was also positively correlated with the levels of p-PKA (r = 0.691, p < 0.05) (Fig. 4a) and the ratio of p-PKA/PKA (r = 0.583, p < 0.05) in the NAc (Fig. 4b) . On the other hand, in the CPu, neither the mRNA levels (Fig. 2b) nor the protein expression of the subunits of GABA A receptors (Fig. 3b, d) were significantly altered by any antipsychotic drug.
It was also observed that the mRNA expression levels of Creb1 (F 3, 20 = 2.952, p < 0.05) were significantly altered by antipsychotic drug administration in the NAc. Post hoc tests indicated that both aripiprazole and haloperidol administration significantly elevated the mRNA levels of Creb1 (aripiprazole 124.1 ± 5.3 %, p < 0.05; haloperidol 125.7 ± 7.7 %, p < 0.01) in the NAc (Fig. 2a) . Western blots indicated that drug administration significantly changed the levels of CREB1 (F 3, 20 = 3.656, p < 0.05) in the NAc. Post hoc tests showed that administration with aripiprazole was able to significantly promote the expression of CREB1 (127.4 ± 5.9 %, p < 0.05) (Fig. 3a, c) in the NAc; additionally, haloperidol also elevated the protein levels of CREB1, but did not reach significance (119.1 ± 6.7 %, p < 0.1). Moreover, the protein expression of CREB1 was positively correlated with the levels of p-PKA (r = 0.371, p < 0.05) (Fig. 4c) , as well as the ratio of p-PKA/PKA (r = 0.750, p < 0.01) in the NAc (Fig. 4d) . On the other hand, in the CPu, no drug administration significantly changed either the mRNA levels of Creb1 (all p > 0.1) (Fig. 2b) or its protein expression (Fig. 3b, d ). 
Discussion
The present study measured the in vivo effects of antipsychotics on PKA signalling in the PFC, NAc and CPu. We observed significant effects on PKA signalling induced by aripiprazole and haloperidol in the NAc and CPu. Aripiprazole and haloperidol, but not bifeprunox, activated PKA phosphorylation in the NAc. However, different effects were observed in the CPu-aripiprazole, unlike haloperidol, inhibited PKA activity in the CPu. Further analysis showed that mRNA expression and protein levels of GABA A receptors (containing β-1 subunit) and CERB1 were upregulated by both aripiprazole and haloperidol administration, and were also significantly correlated with p-PKA levels and/or the ratios of p-PKA/PKA in the NAc. This indicates that aripiprazole and haloperidol might upregulate the expression of GABA A and CREB1 through PKA signalling in the NAc. In the CPu, on the other hand, unexpectedly, GABA A receptors and CREB1 were not significantly altered by aripiprazole and haloperidol, although they changed the ratios of p-PKA/ PKA.
The present study demonstrated that haloperidol enhanced PKA activity in the NAc and CPu by increasing the levels of p-PKA and/or the ratio of p-PKA/PKA. Previously, a study showed the protein levels of PKA-Cα were elevated in the CPu by acute administration with haloperidol, but not in the PFC and NAc (Turalba et al. 2004) . A long-term study revealed that the activity of the cAMP-PKA pathway in the striatum was significantly increased after administration with haloperidol for 3 weeks (Dwivedi et al. 2002) . Our results are consistent with those of previous studies, suggesting that haloperidol is able to antagonise D 2 -like receptors to increase PKA signalling. Furthermore, our study is the first study to examine the effects of aripiprazole; we found increased PKA phosphorylation levels and an increased ratio of p-PKA/PKA in the NAc, which is similar to the effects of haloperidol in this brain region, suggesting its antagonistic effects on D 2 -like receptors. It is interesting that aripiprazole reduced the ratio of p-PKA/PKA in the CPu in the present study, whereas haloperidol increased it. This reduction may indicate that aripiprazole exerts agonistic effects on D 2 -like receptors together with endogenous dopamine in this brain region. Moreover, aripiprazole is a functionally selective ligand for the dopamine D 2 receptor (Han et al. 2009; Mailman and Murthy 2010) . These opposite effects of aripiprazole on PKA signalling in the NAc and CPu might be (at least partly) attributed to its functional selectivity for the D 2 receptor. This may also explain why aripiprazole has fewer EPS side effects than haloperidol, since haloperidol can increase PKA signalling in both the NAc and CPu. Lastly, bifeprunox had no effect on PKA activity in all brain regions in this study, probably because bifeprunox possesses a high level of intrinsic activity (Tadori et al. 2007) , exhibiting overall agonistic effects with endogenous dopamine.
We further observed that haloperidol enhanced PKA activity in the CPu. However, aripiprazole reduced it by decreasing the ratio of p-PKA/PKA, probably due to its functional selectivity for the D 2 receptor, as discussed earlier. It was also revealed that aripiprazole may act as a potent partial agonist, weak agonist, or antagonist depending upon the cellular environments of the targeted D 2 receptors (Burris et al. 2002; Kikuchi et al. 1995; Lawler et al. 1999; Mailman and Murthy 2010; Shapiro et al. 2003; Urban et al. 2007 ). It should be noted that the NAc and CPu are heterogeneous structures with different connections with various brain regions (reviewed by Yager et al. 2015) . For example, the NAc receives dopaminergic inputs from the ventral tegmental area (VTA) and links with limbic areas and the PFC, while the CPu receives dopaminergic inputs from the substantia nigra pars (SN) and links with neocortical areas, particularly the motor areas (Yager et al. 2015) . Blockade of dopamine D 2 receptor activity in the mesolimbic (VTA-NAc) pathway is the common mechanism of antipsychotic actions, particularly in the control of positive symptoms of schizophrenia (Ginovart and Kapur 2012) ; in addition, EPS side effects induced by antipsychotics are related to the blockade of D 2 receptors in the nigrostriatal (SN-CPu) pathway (Tauscher et al. 2002) . Since the cellular environments are distinct between the NAc and CPu, this theory of functional selectivity may be applied to the present study to explain the regional differences of aripiprazole on PKA signalling. However, the previous evidence was primarily based on in vitro studies (Burris et al. 2002; Kikuchi et al. 1995; Lawler et al. 1999; Mailman and Murthy 2010; Shapiro et al. 2003; Tadori et al. 2011; Tadori et al. 2007; Tadori et al. 2005; Urban et al. 2007) , and the in vivo effects of aripiprazole require further investigation. Moreover, in view that the pathological changes in various mental disorders, the extracellular and intracellular environments should be different in the patients' brains from those of the normal subjects. Therefore, it could be reasoned that psychoactive drugs may affect the PKA signalling differently in patients or rodent models for schizophrenia (such as the amphetamine and phencyclidine rat models, neuregulin-1 and ErbB4 knock-out models for schizophrenia, etc.).
Hypofunction of dopamine signalling in the PFC has been found in schizophrenia subjects, and it is believed that this hypofunction of dopamine signalling is connected with the negative symptoms of schizophrenia (Howes and Kapur 2009 ). Therefore, it can be assumed that aripiprazole can exert agonistic effects on D 2 -like receptors under hypodopaminergic conditions. Unexpectedly, we did not observe this agonistic effect in the PFC in the current study. This study used healthy animals with normal dopamine signalling; in this situation, the intrinsic activity of aripiprazole may not be potent enough to increase dopamine signalling when it acts together with endogenous dopamine, so that we could not observe the agonistic effect of aripiprazole while it happens under hypo-dopaminergic condition.
Previous evidence suggests that dysfunction in the GABA system is implicated in the pathophysiology of schizophrenia (Lewis et al. 2004) , and the GABA A receptor can be regulated by D 2 -like receptor-mediated PKA signalling (Connelly et al. 2013; Poisbeau et al. 1999) . In this study, we found that both aripiprazole and haloperidol administration, but not bifeprunox, were able to significantly increase mRNA expression of Gabrb1 in the NAc after 1-week administration, whereas in the CPu no alterations in the GABA A receptor were induced by antipsychotic drug administration. In addition, both aripiprazole and haloperidol elevated the protein expression of GABA A (containing β-1) receptor (although the increasing effect of haloperidol did not reach significance). Previously, it is reported that chronic haloperidol administration increased the binding density of GABA A receptors in the NAc (Zink et al. 2004) , which is consistent with the finding of the present study. However, the effects of antipsychotics on the GABA A receptor are quite brain region-dependent. Zink et al. (2004) also revealed that haloperidol reduced GABA A receptor binding in the temporal and parietal cortex, and both haloperidol and clozapine reduced it in the anterior cingulate and infralimbic cortex. Additionally, 1-week administration with both haloperidol and olanzapine increased the binding of GABA A receptors in the PFC (Skilbeck et al. 2007 ). Tanahashi et al. (2012) and Peselmann et al. (2013) also suggested that aripiprazole affected GABA signalling in a brain region-dependent manner.
In this study, both aripiprazole and haloperidol have the ability to facilitate PKA activity and increase the levels of the GABA A receptor; we also revealed that the mRNA levels of GABA A receptors are positively correlated with both the levels of p-PKA and the ratio of p-PKA/PKA. It is therefore suggested that the regulation of GABA A receptors by antipsychotics in the NAc might occur through regulating PKA signalling via D 2 -like receptors. In addition, since dysfunction of the NAc is involved in the positive symptoms of schizophrenia (Mikell et al. 2009 ) and the positive symptoms could be controlled by blocking D 2 receptors in NAc, our finding further suggests that PKA-GABA A signalling transmission is very likely to be involved in the therapeutic effects of antipsychotics (possibly in the positive symptoms of schizophrenia) (Fig. 5) . On the other hand, antipsychotic administration did not exert any effects on the GABA A receptor in the CPu, whereas significant effects were revealed in the previous study after chronic haloperidol treatment (Zink et al. 2004 ). This discrepancy may be due to the treatment period. It seems likely that antipsychotic administration needs longer to exert a delayed effect on the GABA A receptor in the CPu, but this requires further chronic study to validate.
It should be noted that GABA A signalling was increased in various brain regions in schizophrenia subjects in postmortem studies (Benes et al. 1992; Benes et al. 1997; Dean et al. 1999; Deng and Huang 2006; Hanada et al. 1987; Ishikawa et al. 2004; Woo et al. 2004 ) (although conflicting data existed (Pandey et al. 1997; Squires et al. 1993) ). However, our study exhibited increasing effects of antipsychotics on GABA A signalling in the NAc, which was also reported by Zink et al. (2004) . These findings conflict with the situation observed in schizophrenia patients. Since most schizophrenia subjects have been exposed to chronic antipsychotic treatment, the increased GABA A signalling observed in postmortem tissues might be at least partially a secondary effect of chronic antipsychotic treatment. Additionally, there is no postmortem data that directly describes the changes in GABA A signalling in the NAc of schizophrenia patients, and further related studies are required to address this issue.
Novel variants in the CREB gene have been identified in schizophrenic subjects (Kawanishi et al. 1999; Shaywitz and Greenberg 1999) . CREB can be phosphorylated by PKA and affected by antipsychotic administration (Dash et al. 1991) . Previous studies reported that haloperidol was able to increase phosphorylation levels of CREB both in vivo and in vitro (Konradi and Heckers 1995; Pozzi et al. 2003; Yang et al. 2004 ). In addition, atypical antipsychotics amisulpride and clozapine can also induce phosphorylation of CREB in vitro (Jeon et al. 2015; Park et al. 2011) . The above antipsychotics are all D 2 R antagonists, which may indicate that dis-inhibition of cAMP and activation of PKA via antagonising D 2 -like receptors leads to increased activity of CREB. In the present study, administration with haloperidol significantly increased mRNA expression of CREB1, as well as its protein expression (tended to be significant), in the NAc, which is consistent with those previous findings (Konradi and Heckers 1995; Pozzi et al. 2003; Yang et al. 2004 ). Our study is the first study to examine the in vivo effects of D 2 partial agonists (e.g. aripiprazole) on CREB so far. We observed that aripiprazole had positive effects on elevating the protein expression and mRNA levels of CREB1 in the NAc, whereas bifeprunox had no such effects. Since patients with novel variants in the CREB gene experienced the positive symptoms of schizophrenia (Kawanishi et al. 1999) , upregulation of CREB1 in the NAc is very likely to be associated with the therapeutic effects of antipsychotics on the positive symptoms of schizophrenia. Figure 5 depicts a proposed mechanism indicating that antipsychotics activate PKA signalling via antagonising D 2 -like receptors, and might link to the increase in the expression of CREB1 to exert therapeutic effects on the positive symptoms of schizophrenia.
It is worth noting that CREB activity can also be affected by the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinases (ERK) signalling cascade, and this regulation plays a role in schizophrenia (Kyosseva et al. 1999) . Previously, both ERK and CREB activity were reported to be up-regulated by both haloperidol and risperidone (Yang et al. 2004) . Therefore, MAPK/ERK signalling cascade via D 2 -associated G βγ protein is another possible (probably indirect) signalling pathway by which aripiprazole and haloperidol regulate CREB1 to achieve their therapeutic effects on the positive symptoms of schizophrenia. Therefore, the role of MAPK/ERK-mediated CREB1 activity in the antipsychotic treatment of schizophrenia is worth exploring in the future.
In summary, the present study demonstrated that aripiprazole was able to increase the expression of GABA A (containing β-1 subunit) receptor and CREB1 in the NAc, which were significantly correlated with the enhanced PKA signalling. However, further studies are important to validate whether aripiprazole affects GABA A receptors and CREB1 via D 2 R-mediated PKA pathway by (1) using specific D 2 R antagonists, such as L-741,626 in combination with the antipsychotic drugs, (2) evaluating transcription factor phosphorylation and (3) inhibiting PKA signalling. This study also suggested that aripiprazole may have functionally selective effects on the dopamine D 2 receptor to differentially regulate PKA signalling in the NAc and CPu. Further studies are required to explore what roles the up-regulation of GABA A receptors and CREB1 induced by antipsychotics plays in the treatment of schizophrenia. It is worth noting that the present and previous studies mentioned above examined the effects of antipsychotic drugs on the PKA-related signalling pathways only in healthy animals. It is, therefore, necessary to investigate whether these drugs have similar effects in the animal models for schizophrenia and other mental disorders in future studies. 
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